Abstract
A pilot study was undertaken to assess the feasibility, toxicity, and efficacy of combined radiation therapy and chemotherapy in the adjuvant treatment of node-positive. Stage II patients with breast carcinoma who had undergone lumpectomy. Therapy consisted of three phases, starting with a six-week CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone) induction, followed by radiation therapy to the breast, and concluding with four cycles of VATH (vinblastine, Adriamycin, thiotepa, Halotesin). Twenty-seven patients were entered with an average age of 51.5 years (median 50 yrs) and a mean follow-up of 46.2 months. Twenty-three patients (85.2%) are alive and 19 (70.3%) disease free. There were no ipsilateral local recurrences. Cosmetic results were good to excellent in 26/27 patients. The doses of VATH were not compromised by the prior therapy. The regimen was found to be tolerable and is a reasonable approach in the adjuvant treatment of this particular patient population.
MeSH terms
-
Adjuvants, Pharmaceutic / adverse effects
-
Adjuvants, Pharmaceutic / therapeutic use*
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / mortality
-
Breast Neoplasms / pathology
-
Breast Neoplasms / therapy*
-
Combined Modality Therapy
-
Cyclophosphamide / adverse effects
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / administration & dosage
-
Esthetics
-
Female
-
Fluorouracil / adverse effects
-
Fluorouracil / therapeutic use
-
Fluoxymesterone / administration & dosage
-
Hematologic Diseases / chemically induced
-
Hematologic Diseases / epidemiology
-
Humans
-
Lymphatic Metastasis
-
Mastectomy, Segmental / standards*
-
Methotrexate / adverse effects
-
Methotrexate / therapeutic use
-
Middle Aged
-
Neoplasm Recurrence, Local
-
Neoplasm Staging
-
Pilot Projects
-
Prednisone / adverse effects
-
Prednisone / therapeutic use
-
Radiotherapy / standards*
-
Survival Rate
-
Thiotepa / administration & dosage
-
Vinblastine / administration & dosage
-
Vincristine / adverse effects
-
Vincristine / therapeutic use
Substances
-
Adjuvants, Pharmaceutic
-
Vincristine
-
Vinblastine
-
Doxorubicin
-
Cyclophosphamide
-
Thiotepa
-
Fluoxymesterone
-
Fluorouracil
-
Prednisone
-
Methotrexate